Indian Drug Major Sun Pharma Buys Organon in All-Cash Transaction

Sun Pharmaceutical Industries Ltd on Monday announced that it will acquire US-based Organon & Co in an all-cash deal valued at an enterprise valuation of USD 11.75 billion.

The company said it has signed a definitive agreement to acquire all outstanding shares of Organon for USD 14 per share.

Organon was formed in 2021 as a spinoff from Merck & Co., which is known as MSD outside the United States and Canada.

The acquisition marks one of the biggest overseas deals by an Indian pharmaceutical company and is expected to significantly expand Sun Pharma’s global footprint.

Organon has a strong presence in women’s health, biosimilars, and established medicines, which could complement Sun Pharma’s existing portfolio.

The transaction is subject to customary regulatory approvals and closing conditions.